Nanocrystal technology for drug formulation and delivery

Abstract

With the development of modern technology like high throughput screening, combinatorial chemistry and computer aid drug design, the drug discovery process has been dramatically accelerated. However, new drug candidates often exhibit poor aqueous or even organic medium solubility. Additionally, many of them may have low dissolution velocity and low oral bioavailability. Nanocrystal formulation sheds new light on advanced drug development. Due to small (nano- or micro- meters) sizes, the increased surface-volume ratio leads to dramatically enhanced drug dissolution velocity and saturation solubility. The simplicity in preparation and the potential for various administration routes allow drug nanocrystals to be a novel drug delivery system for specific diseases (i.e. cancer). In addition to the comprehensive review of different technologies and methods in drug nanocrystal preparation, suspension, and stabilization, we will also compare nano- and micro-sized drug crystals in pharmaceutical applications and discuss current nanocrystal drugs on the market and their limitations.

Key words： drug nanocrystal; nanotechnology; formulation; bioavailability; stabilizers; drug delivery

Acknowledgements

This study was supported by NIH Grant GM081874.

References

1 Lipinski C. Poor aqueous solubility-an industry wide problem in drug discovery. American Pharmaceutical Review, 2002, 5: 82–85

2 Peters K, Muller R H. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size reduction technique. International Journal of Pharmaceutics, 1998, 160(2): 229–237

3 Fromming K H S, Fromming J. Cyclodextrines in Pharmacy. Dordrecht: Kluwer Academic, 1993

4 Muller R H. Dispersions for the formulation of slightly or poorly soluble drugs. US Patent, 7060285, 2001

5 Muller B W, Rasenack N. Micro-size drug particles: Common and novel micronization techniques. Pharmaceutical Development and Technology, 2003, 9: 1–13

6 Zhang D, Chen M, Gao L. Drug nanocrystals for the formulation of poorly solubledrugs and its application as a potential drug delivery system. Journal of Nanoparticle Research, 2008, 10(5): 845–862

7 Park J Y, Zhang Y, Liu F. Targeted cancer therapy with novel high drug-loading nanocrystals. Journal of Pharmaceutical Sciences, 2010, 99(8): 3542–3551

8 Luna I P, Sutradhar K B, Khatun S. Increasing possibilities of nanosuspension. Journal of Nanotechnology, 2013, 346581: 1–12

9 Abhijit A D, Kulkarni R M, Patravale V B. Nanosuspensions: A promising drug delivery strategy. Journal of Pharmacy and Pharmacology, 2004, 56(7): 827–840

10 Moschwitzer J P, Muller R H, Sinha B. Bottom-up approaches for preparing drug nanocrystals: Formulations and factors affecting particle size. International Journal of Pharmaceutics, 2013, 453(1): 126–141

11 Merisko-Liversidge E, Liversidge G G, Cooper E R. Nanosizing: a formulation approach for poorly-water-soluble compounds. European Journal of Pharmaceutical Sciences, 2003, 18(2): 113–120

12 Parmentier J, Widzinski M, Tan E H, Gokkhale R, Chin W W L. A brief literature and patent review of nanosuspensions to a final drug product. Journal of Pharmaceutical Sciences, 2014, 103(10): 2980–2999

13 Möschwitzer J P. Drug nanocrystals in the commercial pharmaceutical development process. International Journal of Pharmaceutics, 2013, 453(1): 142–156

14 Cundy G G, Bishop K C, Czekai J F, Liversidge D A. Surface modified drug nanoparticles. US Patent, 5145684, 1992

15 Muller R H, Shegokar R. Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives. International Journal of Pharmaceutics, 2010, 399(1-2): 129–139

16 Liversidge E M, Merisko-Liversidge G G. Drug nanoparticles: Formulating poorly water-soluble compounds. Toxicologic Pathology, 2008, 36(1): 43–48

17 Muller R H, Keck C M. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 62(1): 3–16

18 Muller R H, Moschwitzer J P, Salazar J. Combinative particle size reduction technologies for the production of drug nanocrystals. Journal of Pharmaceutics, 2014, 265754: 1–14

19 Rabinow B E. Nanosupensions in drug delivery. Nature Reviews. Drug Discovery, 2004, 3(9): 785–796

20 Gohla S, Keck C M, Muller R H. State of the art of nanocrystals—Special features, production, nanotoxicology aspects and intracellular delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 78(1): 1–9

21 Haynes D H. Phospholipid-coated microcrystals: Injectable formulations of water insoluble drugs. US Patent, 5091187, 1992

22 Williams H D, Trevaskis N L, Charman S A, Shanker R M, Charman W N, Pouton C W, Porter C J H. Strategies to address low drug solubility in discovery and development. Pharmacological Reviews, 2013, 65(1): 315–499

23 Liversidge G G, Merisko-Liversidge E. Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorly-water soluble compounds using wet media milling technology. Advanced Drug Delivery Reviews, 2011, 63(6): 427–440

24 Muller R H, Junghanns J U A H. Nanocrystal technology, drug delivery and clinical applications. International Journal of Nanomedicine, 2008, 3(3): 295–309

25 Sucker H, Gassmann P. Improvements in pharmaceutical compositions. European Patent, 0580690, 1992

26 List M, Sucker H. Pharmaceutical colloidal hydrosols for injection. GB Patent, 2200048, 1988

27 Sharma S, Aggarwal G. Novel technologies for oral delivery of poorly soluble drugs. Research Journal of Pharmaceutical. Biological and Chemical Sciences, 2010, 1(4): 292–305

28 Bohn H, Auweter H, Heger R, Precipitated water-insoluble colorants in colloid disperse form. US Patent, 6494924, 2002

29 Auweter H, Andr’e V, Horn D, Luddecke E. The function of gelatin in controlled precipitation processes of nanosize particles. Journal of Dispersion Science and Technology, 1998, 19(2-7): 163–184

30 Chan H K, Kwok P C. Production methods for nanodrug particles using the bottom-up approach. Advanced Drug Delivery Rivew, 2011, 63(6): 406–416

31 Pacharane S, Chaudhry A, Jadhav K, Kadam V, Koshy P. Drug particle engineering of poorly water soluble drugs. Der Pharmacia Lettre, 2010, 2(4): 65–76

32 Kaerger J S, Price R. kaerger J S, Price R. Processing of spherical crystalline particles via a novel solution atomization and crystallization by sonication (SAXS) technique. Pharmaceutical Research, 2004, 21(2): 372–381

33 Wang Y H, Guo F, Wang X M, Zheng C, Chen J F. Synthesis of nanoparticles with novel technology: High-gravity reactive precipitation. Industrial & Engineering Chemistry Research, 2000, 39(4): 948–954

34 Zhang J Y, Shen Z G, Zhong J, Yun J, Chen J F. Preparation and characterization of amorphous cefuroxime axetil drug nanoparticles with novel technology: High-gravity antisolvent precipitation. Industrial & Engineering Chemistry Research, 2006, 45(25): 8723–8727

35 Brown J, Chen X, Swinnea S, Williams R O III, Johnston K P, Sarkari M. Enhanced drug dissolution using evaporative precipitation into aqueous solution. International Journal of Pharmaceutics, 2002, 243(1-2): 17–31

36 Sahoo N G, Li L, Judeh Z, Wang Y, Chong K, Loh L, Kakran M. Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension. International Journal of Pharmaceutics, 2010, 383(1-2): 285–292

37 Singh S K, Nagpal K, Girotra P. Supercritical fluid technology: A promising approach in pharmaceutical research. Pharmaceutical Development and Technology, 2013, 18(1): 22–38

38 Montes A, Gordillo M D, Pereyra C, Martinez de la Ossa E J. Particles formation using supercritical fluids. In: Hironori Nakajima, ed. Mass Transfer-Advanced Aspects, 2011, 461–480

39 Turk M. Manufacture of submicron drug particles with enhanced dissolution behaviour by rapid expansion processes. Journal of Supercritical Fluids, 2009, 47(3): 537–545

40 Martín Á, Mattea F, Varona S, Cocero M J. Encapsulation and co-precipitation processes with supercritical fluids: Fundamentals and applications. Journal of Supercritical Fluids, 2009, 47(3): 546–555

41 Kalani M, Yunus R. Application of supercritical antisolvent method in drug encapsulation: A review. International Journal of Nanomedicine, 2011, 6: 1429–1442

42 Rogers T L, Brown J, Young T, Johnston K P, Williams R O III, Hu J. Improvement of dissolution rates of poorly water soluble APIs using novel spray freezing into liquid tecnology. Pharmaceutical Research, 2002, 19(9): 1278–1284

43 Moschwitzer J, Muller R H. New method for the effective production of ultrafine drug nanocrystals. Journal of Nanoscience and Nanotechnology, 2006, 6(9-10): 3145–3153

44 Wong J C T, Doty M J, Rebbeck C L, Kipp J E. Microprecipitation method for preparing submicron suspensions. US Patent, 6869617, 2001

45 Muller R H, Moschwitzer J. Method and device for producing very fine particles and coating such particles. US Patent, 0297565 A1, 2009

46 Gokhale R, Burgess D J, Verma S. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. International Journal of Pharmaceutics, 2009, 380(1-2): 216–222

47 Keck C M, Kobierski S, Mauludin R, Muller R H. Second generation of drug nanocrystals for delivery of poorly soluble drugs: Smart crystal technology. Dosis, 2008, 24(2): 124–128

48 Mchwitzer R H, Bushrab J, Muller F N. Manufacturing of nanoparticles by milling and homogenization techniques. In: Gupta R B, Kompella U B, eds. Nanoparticle Technology for Drug Delivery. New York: CRC Press, 2006, 59: 21–51

49 Reddy I K, Nutan M T H. General Principles of Suspensions. In: Kulshreshtha A K, Singh O N, Wall G M, eds. Pharmaceutical Suspensions. New York: Springer-Verlag, 2009, 39–65

50 Heinzerling O, Salazar J, Muller R H, Moschwitzer J P. Process of optimization of a novel production method for nanosuspensions using design of experiments. International Journal of Pharmaceutics, 2011, 420(2): 395–403

51 Zhang J, Watanabe W, Wu L. Physical and chemical stability of drug nanoparticles. Advanced Drug Delivery Reviews, 2011, 63(6): 456–469

52 Landau B V, Derjaguin L. Theory of the stability of strongly charged lyophobic sols and of the adhesion of strongly charged particles in solutions of electrolytes. Acta Physico-Chimica Sinica, 1941, 14: 633–662

53 Van den Mooter G, Augustijns P, Van Eerdenbrugh B. Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. International Journal of Pharmaceutics, 2008, 364(1): 64–75

54 Wang Z H, Li T L, Lu Y. Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation. Journal of Controlled Release, 2014, 176: 76–85

55 Liu R. Water-Insoluble Drug Formation. Buffalo Grove: Inter-Pharm Press, 2000, 455

56 Tian W, Zhang Y, Sun W, He J, Mao S, Fang L. Effect of novel stabilizers-cationic polymers on the particle size and physical stability of poorly soluble drug nanocrystals. Nanomedicine; Nanotechnology, Biology, and Medicine, 2012, 8(4): 460–467

57 Yoo J Y, Kwak H S, Choi J Y. Role of polymeric stabilizers for drug nanocrystal dispersions. Current Applied Physics, 2005, 5(5): 472–474

58 Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. Journal of Pharmacy and Pharmacology, 2010, 62(11): 1569–1579

59 Chase A R, Gibson G D, Granberg M R, Harvey C B, King S C, Martin R E, Medwick A N, Swinyard T, Zink E A, Gennaro G L. Colloidal dispersions. In: Alfonso R G, ed. Remington’s Pharmaceutical Sciences. Philadelphia: Mack Publishing Co., 1985, 286–289

60 Hartenhauer N, Muller R H, Rasenack B W. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. International Journal of Pharmaceutics, 2003, 254(2): 137–145

61 Muller N, Rasenack B W. Dissolution rate enhancement by in-situ-micronization of poorly water-soluble drugs using a controlled crystallization process. Pharmaceutical Research, 2002, 19: 1896–1902

62 Chandrasekhar V S R, Katteboinaa S. Drug nanocrystals: a novel formulation approach for poorly soluble drugs. International Journal of Pharm Tech Research, 2009, 1(3): 682–694

63 Whitney W R, Noyes A A. The rate of solution of solid substances in their own solutions. Journal of the American Chemical Society, 1897, 19(12): 930–934

64 Mehta S C, Higuchi W I, Simonelli A P. Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. Journal of Pharmaceutical Sciences, 1970, 59: 633–638

65 Ponchel G, Duchene D. Bioadhesion of solid oral dosageforms, why and how? European Journal of Pharmaceutics and Biopharmaceutics, 1997, 44(1): 15–23

66 Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Maincent P, Kawashima Y, Lehr C M. Biodegradable nanoparticles for targeted drug delivery intreatment ofinflammatory bowel disease. Journal of Pharmacology and Experimental Therapeutics, 2001, 299(2): 775–781

67 Jaitley V, Florence A T, Hussain N. Recent advancesin the understanding of uptake of microparticulates acrossthe gastrointestinallymphatic. Advanced Drug Delivery Reviews, 2001, 50(12): 107–142

68 Muller R H, Jacobs C. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharmaceutical Research, 2002, 19(2): 189–194

69 Gangwal R P, Sangamwar A T, Jain S, Thanki K. Oral delivery of anticancer drugs: Challenges and opportunities. Journal of Controlled Release, 2013, 170(1): 15–40

70 Jacobs C, Kayser O, Muller R H. Production and characterisation of muco adhesive nanosuspensions for the formulation of bupravaquone. International Journal of Pharmaceutics, 2001, 214(1-2): 3–7

71 Conzentino G G, Liversidge P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. International Journal of Pharmaceutics, 1995, 125(2): 309–313

72 Engers W M, Mueller D A, Eickhoff K R. Nanoparticulate NSAID Compositions, Application. US Patent, 5518738 A, 1996

73 Kayser O, Olbrich C, Yardley V, Kiderlen A F, Croft S L. Formulation of amphotericin B as nanosuspension for oral administration. International Journal of Pharmaceutics, 2003, 254(1): 73–75

74 Tu Z, Ng C, Yang Y, Liang J F, Agresti C. Specific interactions between diphenhydramine and alpha-helical poly(glutamic acid)-a new ion-pairing complex for taste masking and pH-controlled diphenhydramine release. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70(1): 226–233

75 Garg A, Aggarwal D, Singla A K. Paclitaxel and its formulations. International Journal of Pharmaceutics, 2002, 235(1-2): 179–192

76 Peters K, Leitjke S, Diederichs J E, Borner K, Hahn H, Muller R H, Ehlers S. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. Journal of Antimicrobial Chemotherapy, 2000, 45(1): 77–83

77 Kayser O, Steckel H, Muller R H, Hernandez-Trejo N. Characterization of nebulised buparvaquone nanosuspension—effect of nebulization technology. Journal of Drug Targeting, 2005, 13(8-9): 499–507

78 Kayser O, Muller R H, Steckel H, Hernandez-Trejo N. Physical stability of buparvaquone nanosuspensions following nebulization with jet and ultrasonic nebulizers. In: Proceedings of the International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Nuremberg Germany, 2004

79 Montisci M J, Dembri A, Ponchel G, Durrer C, Duchene D. Mucoadhesion of colloidal particulate systems in the gasrointesinal tract. European Journal of Pharmaceutics and Biopharmaceutics, 1997, 4: 25–31

80 Aggarwal P, Hall J B, McLeland C B, Dobrovolskaia M A, McNeil S E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Advanced Drug Delivery Reviews, 2009, 61(6): 428–437

81 Liu Y, Huang L, Liu F. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Molecular Pharmaceutics, 2010, 7(3): 863–869

82 Kayser O. Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against Leishmania infected macrophages. International Journal of Pharmaceutics, 2000, 196(2): 253–256

83 Mansell P. Nanocrystals could be route to carrier-free drug delivery. in-Pharma, 2007

84 Singh Y, Meher J G, Pawar V K, Gupta S, Chourasia M K. Engineered nanocrystal technology: In-vivo fate, targeting and applications in drug delivery. Journal of Controlled Release, 2014, 183: 51–66

85 Bansal M, Kumria R, Bansal S. Nanocrystals: Current strategies and trends. International Journal of Research in Pharmaceutical and Biomedical Sciences, 2012, 3(1): 406–419